Biotehc firm Rigel’s (RIGL) rheumatoid arthritis drug candidate R788 did not meet its primary endpoint in Phase IIb clinical trial, probably putting in question the company’s goal of securing a R788 partner by the first half of 2010. In a odd twist, the main reason R788 failed the efficacy portion of the 219-patient study is because [[ This is a content summary only.
Posts Tagged rigl
Here are some of the top stories affecting key drug and biotech stocks that have links through to more in-depth coverage and analysis today at the website BioHealthInvestor.com: Rigel Pharmaceuticals Inc.’s (NASDAQ: RIGL) Phase IIb trial results Thursday morning of its rheumatoid arthritis candidate R788, is boosting its stock on speculation it may help the company [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
These are some of the this morning’s top day trader alert stocks to watch based on pre-market and after-hours volume activity. These have links through to more detailed trading and volume analysis covered at the Volume Spike site VSInvestor.com: Alcoa Inc. (NYSE: AA) shares are ones to watch for a volume spike higher after the company [[ This is a content summary only.
